Role of Crystallization in Genesis of Diverse Crystal Forms of Antidiabetic Agents by Chadha, Renu et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 6
Role of Crystallization in Genesis of Diverse Crystal
Forms of Antidiabetic Agents
Renu Chadha, Dimpy Rani and Parnika Goyal
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/59674
1. Introduction
Crystallization is a crucial step in the manufacturing and processing of active pharmaceutical
ingredients (API’s) in pharmaceutical industry [1]. As crystallization is coupled with molecular
recognition, a slight alteration in crystallization conditions can affect crystal and powder
properties accompanied with thermodynamic and mechanical properties [2]. So, the selection
of an appropriate solid form of an active pharmaceutical ingredient (API) in the early stages
of drug development is very important as it can be pure crystalline form or its non covalent
modification such as polymorph, amorphate, hydrate, solvate, salt or co-crystals exhibiting
unique physicochemical properties (solubility, dissolution rates, stability and bioavailability)
and other performances characteristics of drug [3].
Existence of a crystalline solid into many crystalline forms leads to polymorphism which is a
phenomenon, hard to predict. It may be of two types either conformational (due to existence
of various conformers of molecule) or packing polymorphism (due to difference in crystal
packing). On thermodynamic consideration, there are also two types of polymorphism i.e.,
monotropic system (when the transition of one form to another is irreversible) and enantio‐
tropic system (reversible forms) [4]. In general, least stable crystal form crystallizes out first,
not the most stable form. Metastable crystal form (unstable) tend to change to more stable from
under particular conditions [5]. Crystal forms are the entities which are similar at molecular
level but dissimilar in supramolecular aspect [6].
The various conditions used in the process of crystallization is the chief cause of generation of
different crystal forms of a molecule and the difference in the properties of various crystal
forms is due to different crystal packing and lattice energy [4]. Advancement in synthesis has
gained control on the synthesis and purity of drugs but still lag behind in controlling the
© 2015 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and eproduction in any medium, provided the original work is properly cited.
crystallinity and physical crystal forms. Different forms of a crystalline solid can be controlled
by controlling the crystallization process.
The best method used for obtaining the variety of crystal forms is crystallization as it is
traditional, easy and unbeatable process. Crystallization techniques may be solvent or non-
solvent based and varied methods give rise to different forms. Solvent crystallization techni‐
ques include solvent evaporation, slow cooling of the solution, diffusion, vapour diffusion
while non solvent techniques include sublimation, thermal treatment, desolvation of solvates,
grinding and crystallization from melt etc. The choice of appropriate technique may be decided
depending on the amount of sample and physical stability or solubility of drug [7-8].
Different crystal forms due to different crystal lattice have different physicochemical proper‐
ties and thus therapeutic effects. Thus, Pharmaceutical companies usually search for a crystal
form or polymorph with the best properties for therapeutic use and manufacturability.
Selection of an optimized crystal form is of more relevance as regulatory bodies are showing
their interest in physico-chemical characterization of APIs. Polymorphism is also important to
be considered because this phenomenon is not exhibited by only drug molecule but also by
other solid forms prepared by drug using crystal engineering approaches like salts, solvates,
co-crystals etc. However, the discovery and genesis of various crystal forms is quite tiresome
and expensive [9-12].
This chapter has focused on the various crystal forms of anti-diabetic agents and techniques
employed in their preparation.
Diabetes mellitus is an unceasing disease in the society that requires life-long pharmacological
and non-pharmacological management. Among this, type 2 diabetes mellitus is more preva‐
lent. For the management of type 2 diabetes mellitus, various oral agents have been approved.
The main problem of these agents is their dissolution limited bioavailability. To overcome this
issue various attempts like CD complexes, solid dispersion, crystal engineering approaches
and exploring the more soluble polymorphic form have been made.
2. Case studies of crystal forms of antidiabetics
Several crystalline forms of anti-diabetics have been described in the past. A general account
of different crystal forms, their method of preparation along with transition / melting temper‐
ature are detailed in table 1.
3. Sulfonyluraeas
3.1. Acetohexamide
Potentiality of polymorphism in acetohexamide was first observed by Girgis-Takla and
Chroneos in 1977. They reported two polymorphic forms (polymorphs A and B), distinguished
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by IR spectra and further characterized by Mueller and Lagas. However, forms showed no
notable differenceon drying at 60°C in vaccum [13-14]. Graf et al. proposed keto-enoltauto‐
merism for their stability, confirmed by IR spectra. Polymorph A (enol form) forms six
membered ring via bonding of an O—H and S=O group intramolecularly while polymorph B
(keto form) shows intermolecular bonding of C=O of urea to a sulphonamide N—H [15-16].
Kuroda et al. collected three crystal forms (Form I, Form II and CHCl3 – II) out of which one
was found to be chloroform solvate. Form II was found to be 1.2 times more soluble than Form
I [17].Yokoyama et al. estimated the thermodynamic values (transition temperature - 154°C &
heat of transition - 230°C) of crystal forms (Form I and Form II) from solubility studies. Both
forms were found equally bioavailable inbeagle dogs [18].Another forms Form IV by Graf et
al and Form II and III by Al-Saieq and Rileywere investigated [19-20]. Later Graf et al. found
that Form II was mixture of I and IV, while Form III (by Al-Saieq and Riley) on heating,
converted to a new polymorph V [15].
Another crystal form of acetohexamide (Form VI) by Aldawsariet al. was reportedand was
more soluble in water, and more bio-available in rats as compared to other already reported
crystal forms [21].
3.2. Chlorpropamide
Various publications on the crystal forms (about 16) of chlorpropamide were reported (by
Simmons et al., Burger et al., and Saieq et al.)[22-24], but the provided data could not distinguish
existing crystal forms in actual [1-3]. Ueda et al. depicted convex shaped dissolution curve for
Form C (by simmons et al.) and Form II (by saieq et al.)that indicates crystallization along with
anhydrate to hydrate phase transformation [25].
After that, Debrushchaket al. adopted a new methodology for nomenclature (α, β, γ, δ, ε) on
the basis of the order of their crystal structure established. Form α, β, γ and δ correspond to
previously  reported  Form  III,  II,  IV  and  VI  respectively  and  was  found  that  all  forms
transformed to ε (Form I) crystal form.On cooling up to 200 K, crystal form ε, converted to
another new form (ε’). This new form resembled to α form in aspect of cell parameters and
molecular conformation while to ε form in case of packing (Z shaped ribbons). Form α, β, γ
has same intermolecular hydrogen bonding but differ in packing and number of molecules
in unit cell [26-30].
Bifurcated intermolecular hydrogen bonding pattern of carbonyl group has been seen with
the two amine hydrogen atoms, and SO2 oxygen atom acquires hydrogen from the nitrogen
attached to alkyl tail.With regard to enthalpy of transition, conversion of α, β, γ and δ to ε
should be in order of β > γ > δ > α but β polymorph infracts it because of structural differ‐
ence [31].
All these polymorphs are conformational polymorphs as they showed difference in torsion
angles. (as shown in figure 1) [32]
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Figure 1. Chlorpropamide with possible torsion angles [32]
Process of crystallization was also found to be affected by the presence or absence of 2-
hydroxybutyl-β-cyclodextrin as chlorpropamide crystallized to metastable Form II and III in
presence, whereasto Form A in the absence at 4◦C. Even the appearance of crystal form was
dependent on the concentration and temperature [33].
3.3. Tolbutamide
Several Tolbutamide polymorphs are reported by several groups of workers. [34-42]. Two
forms reported by Simmons et al[34] (Forms A and B) are identical with the Burger’s Form I
and III [35], respectively, and have been well characterized. However, Burger’s Forms II and
IV have been not fully characterized.
3.4. Glimepiride
Two polymorphs (Form I and II) are reported in literature. New crystalline form (Form II) was
prepared by recrystallization from an ethanol/water system was found to have different
dissolution profile and solubility [43] and it transformed to Form I over 140°C.
3.5. Glibenclamide
Crystallisation of glibenclamide from different solvents and quick cooling of melt gave three
polymorphic forms and pseudopolymorphs (solvates), which were significantly different with
regard to solubility and melting properties. [44-45] A new crystalline form of glibencla‐
mide,with higher melting point (218°C) and lower solubility, was formed during an attempt
to elucidate transitional phases by melting, cooling and reheating by A. Panagopoulou-
Kaplani, et al[46].
4. Meglitinides
4.1. Nateglinide
Various solvates/ hydrates (about 26) of nateglinide have been patented which eventually
converts to either Form B or Form H. [47] The S polymorph was crystallized from the melt or
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by isothermal treatment of B or H forms at temperatures higher than their melting points which
is the only stable form, while the polymorphs B and H are metastable forms. The anhydrous
polymorph, if stored at room temperature and humidity, gradually changes to H polymorph
while, if stored in water vapour saturated atmosphere, it gets back water and reverts to the
hemihydrate form. On the contrary, both an isothermal treatment at 80 ◦C and melt cooling
bring to the B polymorph [48].
4.2. Repaglinide
S enantiomer of repaglinide was found active hypoglycemic agent andthree crystalline forms
(Form I, II and III) were crystallized from various solvents by solvent/antisolvent and slow
evaporation method. Form II (low melting crystal form) on further heating showed second
melting endotherm at 127-130°C and converted to Form I if crystallized in ethanol/water
mixture [49].
5. Biguanides
5.1. Metformin hydrochloride
Two polymorphs (form A and B) has been identified out of which form A is more thermody‐
namically more stable while highly metastable structure, which correlates with the difficulty
in handling this polymorph [50]. These two polymorphs and their mixture has been evaluated
by Scott L. Childs, et al using capillary crystallization and thermal microscopy techniques.
Crystal structure of these forms arereported [51]. Both structures are monoclinic (P21/c) with
one complete metformin cation and one chloride anion in the asymmetric unit as shown in
figure 2.
           
Figure 2. Metformin hydrochloride Form A and B shown, respectively at 50% probability ellipsoids. [50]
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6. Thiazolididiones
6.1. Rosiglitazone
Various crystalline forms of maleate salt of rosiglitazone are reported in literature. Choudary
et al. and Blackler et al. put illumination on crystalline hydrates of salt [52-54]. Chebiyyam et
al. described four crystalline forms (Form I, II, III and IN) while Birari et al. described two forms
(Form A and B). Form A was detected more stable than B and all the other crystal forms,
amorphous form, hydrate and anhydrate converted to Form A [55-56]. Kansalet al. depicted
three crystal forms (Form I, III and IV) for hydrobromide salt of rosiglitazone and formulated
Form III in compacted dosage form, while Greil et al. elaborated two hydrates (Form A and
C), one solvate (Form D) and three anhydrate (Form B, B1 and E). 1:1 hydrates were recovered
which may lose their water content at different temperature. Form B and B1 have shown same
melting endotherm temperature but they were distinguished by PXRD [57-58].
6.2. Pioglitazone hydrochloride
Only two polymorphic form I and II has been evaluated which are patented [59].
6.3. Troglitazone
Various crystalline forms of troglitazone are patented. Polymorphs 1,2,3 and 6 are obtained
by different modes of recrystallization while form 4 and 5 are derived by heating any one of
the form 1, 2, 3 or 6 [60].
7. Dipeptidyl peptidase-4 inhibitor
7.1. Alogliptin
In literature, six crystal forms of tartrate (Form A, B, C, D, E and F) and one crystalline form
of benzoate salt of alogliptin (Form A) were reported. Among the crystal forms of alogliptin
tartrate, Form A was found to be more stable and all forms during stability studies converted
to Form A. The most stable form were analyzed for solubility and alsoestablished thermally
stable up to 200°C and a variable hydrate.
Form A of benzoate salt was found to be much stable and amorphous form converted to stable
Form A during heating [61-62].
7.2. Linagliptin benzoate
Crystalline forms of linagliptin benzoate have been patented. Form II is less hygroscopic then
Form I. Thus, can be easily handled in standard pharmaceutical processing conditions and no
special packing is required during its storage [63].
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7.3. Sitagliptin
Numerous solvates and crystal forms of sitagliptin phosphate have been patented. All the
reported crystalline solvates converted to Form II on desolvation and on heating metastable
Form II converted to Form I (at 45°C) and to Form III at 110°C. Form I (stable at higher
temperature) and Form III (stable at lower temperature) have enantiotropic relation [64]. Form
IV, also a metastable form, slowly converted to crystalline sitagliptin phosphate monohydrate
[65]. Huang et al. prepared Form V and processed them to pharmaceutical formulation [66].
7.4. Saxagliptin
Monohydrate, hemihydrates and mixture of thereof of saxagliptin had been prepared and
patented [67].Nine polymorphic forms of saxagliptin hydrochloride (Form K, T, Z, N, S, O, B,
C and D) had been evaluated either from its amorphous form or dihyrate form and being
patented. Forms K, S, N and Z are polymorphically pure, Form D is a hydrate, Form T is in a
mixture with ammonium chloride, Form O is in a mixture with form K and saxagliptinmono‐
chydrochloridemonohydtare while Form B is in a mixture with saxagliptinmonochydrochlor‐
idedihyrate [68]
Drug Crystal form Solvent used Method ofpreparation
Transition (T)/
Melting
endotherms(M)
References
ACETOHEXAMIDE
N
O
HN
SO O
O
Polymorph A Glacial aceticacid Slow evaporation 180-183°C [13]
Polymorph B Chloroform Slow evaporation 183-185°C
Form I
(triclinic)
Ethanol/
methanol/
acetone
Slow evaporation 187°C
[17]Form II
(monoclinic)
Ethanol: water
(1:1)
Heating, slow
evaporation
157°C (T), 186°C
(M)
CHCl3 – II Hot chloroform Slow evaporation
164–169°C (T),
182°C (M)
Form IV Hot benzene Slow evaporation 184-186°C [19]
Form II
(mixture of I
and IV)
Hot Isobutanol Slow evaporation 176-178°C
[20]
Form III Chloroform
Rapid cooling of
saturated
solution at 55°C
-
Form V - Heating Form IIIat 160°C - [19]
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Drug Crystal form Solvent used Method ofpreparation
Transition (T)/
Melting
endotherms(M)
References
Form VI
HP-β-CD in
sodium
phosphate buffer
of pH 8.0
Titration to 0.5 M
HCl, filteration,
cooling
- [21]
CHLORPROPAMIDE
O
O NH
NH
O
Cl
Form A/
III/ /IV
Ethanol-water
mixture Slow evaporation 121-122°C
[22-24]Form B /II /V -
Recystallization
from melt of
Form A
124-127°C
Form C /I - Heat Form A at120°C 128-130°C
Form IV Carbontetrachloride Slow evaporation 122-123°C [23]
Form V Benzene Desolvation ofbenzene solvate < 118°C
Form II Chloroform Rapidevaporation - [24]
Form III Hexanol Rapid cooling -
Form α
(orthorhombic) Ethanol Slow evaporation
124°C (T),
127-128°C (M) [26]
Form β
(orthorhombic)
Heptane-ethyl
acetate
Solvent-
antisolvent
addition
125-127°C
[27]
Form γ
(monoclinic)
Heptanes: ethyl
acetate (1:2) Freezing at -20°C
120°C (T), 128°C
(M)
Form δ
(orthorhombic)
Heptanes: ethyl
acetate (2:1) Slow evaporation
124°C (T), 128°C
(M)
Form ε
(orthorhombic) -
Solid
transformation of
Form α
128°C
TOLBUTAMIDE
O
O NH
O
NH
Form I Benzene: hexane(2:1)
Solvent-
antisolvent
addition, slow
evaporation
127°C
[38]
Form II -
Form IV stored at
60°C, 75% RH,
10min.
100°C (T), 127°C
(M)
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Drug Crystal form Solvent used Method ofpreparation
Transition (T)/
Melting
endotherms(M)
References
Form III Ethanol: water(2:1)
Solvent-
antisolvent
addition, slow
evaporation
113°C (T), 127°C
(M)
Form IV Ethanol: DCM(1.2:1) Spray drying
80°C, 100°C (T),
127°C (M)
Form V Conc. HNO3,methanol
Cocrystallisation
with p-
nitrophenol, p-
phenylenediboro
nic Acid in
ethanol
- [69]
GLIMEPIRIDE
O
NH
O
S
O
O
HN
HN
O
Form I Ethanol andchloroform Slow evaporation 207°C [43]
Form II Ethanol: water(1:1)
Heating, slow
evaporation
140°C (T), 207°C
(M) [70]
GLIBENCLAMIDE
H
N
O
S
O
ON
HNH
O
Cl
Form I - Slow evaporation 174°C [45]Form III - Slow evaporation 153°C
Solvate pentanol/ toulene Slow evaporation 109°C [44]
New Form -
Sublimation of
glassy state at
130-160 °C
218 °C
[46]
Glassy form - Quench coolingof melt
42- 56°C (T),
90-135°C
(exotherm),
198°C (M)
NATEGLINIDE
OH
NH
O
Form B Methanol: water(7:3) Cooling at 10°C 128-130°C [71]
Form H Acetone: water(2:3) Cooling at 10°C 138-141°C
Form S -
Melting/
isothermal
treatment of
Form B/H
172 °C [48]
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Drug Crystal form Solvent used Method ofpreparation
Transition (T)/
Melting
endotherms(M)
References
S-REPAGLINIDE
HO
O
HN
N
O
Form I
Ethanol/water
(2:1), acetone/pet
ether, methanol/
water, THF/
MTBE, ethyl
acetate/pet ether,
n-propanol/
water, ACN/
water, MIBK/
MTB, diethyl
ketone/MTB, t-
butanol/water,
methyl ethyl
ketone/n-
heptane,
diglyme/n-
heptane, methyl
ethyl ketone/
MTBE, 1,4-
dioxane/n-
heptane, n-
butanol/MTBE,
chloroform/n-
hexane
Solvent-
antisolvent, slow
evaporation
130-131°C
[49]
Form II
Pet ether: toluene
(5:3) Rapid cooling 99-101°C
Toluene Heating followedby cooling
Form III (from
Form I, II and
amorphous
form)
Dichloromethane
and pet ether
Cooling and
stirring 80-84°C
METFORMIN
HYDROCHLORIDE
HN NH2
NH NH
H Cl
Form A Methanol: water(2:1) slow evaporation -
[50]
Form B Acetone: water(3:1) slow evaporation -
ROSIGLITAZONE MALEATE Hydrate
Acetonitrile:
water (30:1)/
THF: water
Heating followed
by cooling - [52]
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Drug Crystal form Solvent used Method ofpreparation
Transition (T)/
Melting
endotherms(M)
References
NH
O
O
O
N
N
O
HO
O
HO
(30:1)/ methyl
ethyl ketone:
water (30:1)/
ethyl acetate:
water (100:1)/
isopropanol:
water (33:1)
Hydrate
Ethanol and
water (2.1%v/v)
Heating followed
by cooling
- [53-54]
Methanol-water/
acetonitrile-
water/ ethanol-
water
Heating followed
by cooling
Methanol-water Heating followedby cooling
Water Heating followedby cooling
Ethyl acetate-
water
Heating followed
by cooling
Form I Ethanol Heating followedby cooling 100.53°C
[55]
Form II Acetone Heating followedby cooling 127.67°C
Form III Methanol Heating followedby cooling 126.41°C
Form IN 1,4-dioxane Heating followedby cooling 125.39°C
Form A
Methanol-ethyl
acetate
Heating solution
in methanol
followed by
addition of ethyl
acetate
[56]
Acetonitrile
Heating the
solution followed
by reflux and
cooled
Form B Isopropyl alcohol Heating followedby cooling -
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Drug Crystal form Solvent used Method ofpreparation
Transition (T)/
Melting
endotherms(M)
References
Methanol
Addition of
methanol to
acetone solution
of salt
Isopropyl
alcohol / THF
Heating of
Suspension of
Form A followed
by cooling
- Heating followedby cooling
ROSIGLITAZONE
HYDROBROMIDE
HN
O
O
O
N
N
H
Br
Form I Acetone Reflux, cooling -
[57]
Form III Demineralisedwater Reflux, cooling -
Form IV Acetone Heating Form Iin acetone -
ROSIGLITAZONE PHOSPHATE
NH
O
O
O
N
N
P
OHO
HO OH
Form A
Acetone and
water
Stirring of
suspension 171-177°C
[58]
Ethanol and
water
Stirring of
suspension
Form B Acetone andwater
Stirring of
suspension 175-176°C
Form B1 - Stirring ofsuspension 175-176°C
Form C Acetone: water(1:1)
Phosphoric acid
added to solution
of Form B -Stirring of
suspension of
Form A
Form D Methanol
Heating of
suspension of
Form A
-
Form E Ethanol Heating followedby cooling 167-172°C
PIOGLITAZONE
HYDROCHLORIDE Form I
DMF/ Methanol/
acetic acid
Heating followed
by cooling 198°C [59]
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Drug Crystal form Solvent used Method ofpreparation
Transition (T)/
Melting
endotherms(M)
References
HN
O
O
O N
H
Cl
Form II Acetic acid,water
Heating followed
by cooling 183°C
TROGLITAZONE
HN
O
O
O
O
OH
Form 1 Benzene: acetone(100: 1) Slow evaporation 179°C
[60]
Form 2
Benzene
extraction, DCM
added
Fast evaporation
at -10°C
110°C (T), 175°C
(M)
Form 3 Acetone: benzene(1:2) Cooling at 5°C 185°C
Form 4 - Form I heated tomelt
56°C (T), 110 °C
(exotherm),
177°C (M)
Form 5 - Heating of FormIV at 130 °C
157°C
(exotherm),
180°C (M)
Form 6 Acetone: benzene(1:4)
Cooling of
solution of Form
I at 5 °C
105°C
ALOGLIPTIN TARTRATE
N
N
O O
N
H2N HO
OH
O
OH
O
OH
Form A
Acetone: water
(2:3) or methanol
Filtration, slow
evaporation
172.5°C
[61]
Hot methanol
and acetone/
methanol and
toluene
Cold acetone/
toluene was
added in filtered
solution of hot
methanol and
alogliptin
tartrate, slow
evaporation
water Heating, slowevaporation
Form B
Tetrahydrofuran:
water (2:1)/
dioxane: water
(2:1) /
acetonitrile:
water (4:3)
Filtration, slow
evaporation 124.4°C
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Drug Crystal form Solvent used Method ofpreparation
Transition (T)/
Melting
endotherms(M)
References
Form C
Ethanol: water
(1:1) /
isopropanol:
water (1:1)
Filtration, slow
evaporation 122.4°C
Form D
water
Heating at 80°C,
filtered and
cooling
173.3°C
methanol
Placed
amorphous form
with methanol in
sealed chamber
for several weeks
Form E
Water:
acetonitrile
(4:21) / water:
dioxane (2:1)
Heating at 50°C,
filtered, slow
evaporation
121.9°C
Form F -
Placed
amorphous form
with saturated
salt solution at
84% RH in sealed
chamber
-
ALOGLIPTIN BENZOATE
N
N
O
O
N
NH2
O
OH
Form A
Acetone /
Methanol
Filtration, fast
evaporation
186°C [62]Acetonitrile
Heating slurry at
60°C, filtration,
slow evaporation
Ethanol:
isopropyl acetate
(99:1)
Reflux, cooling
LINAGLIPTIN BENZOATE
N
N
N
O
O
N
N
N NH2
O
HO
Form I Isopropanol Slow evaporation -
[63]Form II Acetonitrile Slow evaporation 193°C
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Drug Crystal form Solvent used Method ofpreparation
Transition (T)/
Melting
endotherms(M)
References
SITAGLIPTIN PHOSPHATE
P O
OHHO
HO
F
F
F
N
N
N
N
F
F F
H2N
Solvate
Methanol/
ethanol/ 1-
propanol/ 2-
propanol/
acetone/
acedtonitrile
By contacting
with solvent for 5
minutes
213.61°C
[64]
Form I Isoamyl alcohol/water Slow evaporation
215.37°C (T),
217.27°C (M)
Form II - Desolvation ofethanol solvate
114.6°C (T),
213.80°C (M)
Form III Isoamyl alcohol/water Slow evaporation
80.90°C (T),
215.94°C (M)
Form IV -
Heating
monohydrate
form above 58°C
213.3°C [65]
Form V
Methanol-water/
acetone-water
Heating followed
by cooling
214.88°C [66]Methanol, n-butanone, THF,
ACN, DMC and
water
Distillation at
55°C
SAXAGLIPTIN
NO
HO
H2N
H
H
Form H-1
(monohydrate)
Ethanol Kept in
desiccator in
atmosphere of
respective
solvents
- [67]
Dibutylether
Water, 80% RH
SAXAGLIPTIN
HYDROCHLORIDE
NO
HO
H2N
H Cl
H
H
Form K Ethyl acetate,Conc. HCl Reflux, cooling -
[68]
Form T
Saturated
ammonium
chloride pH 4.53
Precipitation -
Form Z
(Dihydrate)
Ethyl alcohol,
Methylisopropyl
ketone
Precipitation -
Form N 2- butanol Reflux, cooling -
Form S Wet ethyl acetate,Conc. HCl
Heating followed
by cooling -
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Drug Crystal form Solvent used Method ofpreparation
Transition (T)/
Melting
endotherms(M)
References
Form O 0.8 M HCl/ Ethylalcohol
Heating followed
by cooling -
Form B
Ethyl alcohol,
Methylethylketo
ne
stirring -
Form C Propyl alcohol Heating followedby cooling -
Form D
(hydrate) 1-butanol Heating, stirring -
Table 1. Crystalline Forms of Antidiabetics
8. Conclusion
The crystallization process has profound impact on crystal forms, which further affect
biopharmaceutical properties of pharmaceutical solids. Various crystal forms of antidiabetics
have been reported in literature and some have even gained the status of a patent. The existence
of these different crystal forms are possible due to presence of sulphoxamide, carboxamide,
thiazolidendione, etc. groups in these agents. For the optimized pharmaceutical acceptable
solid form, one must be cognizant of the potentiality of an API to exist in various crystal forms
by altering the crystallization conditions. Because of this, screening of new crystal forms of
API’s has become a vital part of drug discovery and development in past decade.
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